Inhibition of EZH2 and its downregulation by TKI therapy blocks survival of leukemia-initiating cells and promotes CML LSCs apoptosis without impairing normal HSCs by modulation PTEN expression. This evidence concerns the gene EZH2 and chronic myelogenous leukemia, BCR-ABL1 positive.